<PAGE>
                                                                   Exhibit 10.68


              EXCLUSIVE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT

THIS EXCLUSIVE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT (this "Agreement"), is
made as of July 1, 2004, by and between Leiner Health Products, LLC, (a Delaware
limited liability company) having offices at 901 East 233rd Street, Carson,
California 90745 ("Leiner"), and Impax Laboratories, Inc. (a Delaware
corporation), having offices at 30831 Huntwood Avenue, Hayward, California and
3735 Castor Avenue Philadelphia, Pennsylvania ("Impax").

         WHEREAS, Impax has received the United States Food and Drug
Administration's ("FDA") final abbreviated new drug application ("ANDA")
approval for the manufacture and sale of loratadine ten milligram (10 mg)
/pseudoephedrine sulfate 240 milligram (240 mg.) twenty-four (24) hour
decongestant combination tablets (the bioequivalent to Claritin(R)) (the
"Product"); and

         WHEREAS, Impax desires to provide Product exclusively to Leiner, other
than as set forth herein, to enable Leiner to market and sell the Product under
a private label, over-the-counter for all uses allowed by the FDA under Impax's
ANDA for the Product, within the Territory, for all indications as provided
herein; and

         WHEREAS, Leiner desires to obtain Product exclusively from Impax to
enable Leiner to market and sell over-the-counter, for all indications, private
label Product within the Territory, all subject to the terms and conditions set
forth herein.

         NOW, THEREFORE, the parties agree as follows with the intent to be
legally bound:

         1. DEFINITIONS. For purposes hereof, the following terms shall have the
meanings set forth below:

         "Act" means the Federal Food, Drug, and Cosmetic Act, as amended from
time to time, and the rules and regulations promulgated thereunder.

         "Affiliate" means, with respect to any Person, any other Person
controlled by, controlling or under common control with such Person, where
control means more than 50% ownership or voting rights of a Person or the power
to direct the management or policy of a Person.

         "API" means the active pharmaceutical ingredient, loratadine HCl.

         "cGMP" means the current Good Manufacturing Practices regulations of
the FDA (as in effect from time to time) in 21 C.F.R. pts. 210 and 211, as
applicable, to the manufacture, processing, packaging, handling, storage and
control of the Product in the Territory, as same may be supplemented and/or
amended from time to time during the term of this Agreement.

         "Commercially Reasonable Efforts" means efforts and resources normally
used by a Person for a compound or product owned by it or to which it has
rights, which is of similar market potential as the Product and at a similar
stage in its product life, taking into account the competitiveness of the
marketplace, the proprietary position of the compound or product, the regulatory
structure involved, the profitability of the applicable products, and other
relevant factors. It is anticipated that the level of effort and resources may
change at different times during the product life cycle of a compound or
product.

         "Competing Product" means any finished pharmaceutical product available
for sale in the over-the-counter marketplace that contains the same active
ingredients in the same or a similar dosage form and strength as the Product in
a twenty-four (24) hour decongestant dosage form bioequivalent to Claritin(R)
D-24.

         "Confidential Information" means any information which in any way shall
relate to a disclosing party, including, without limitation, its products,
business, know-how, methods, trade secrets and technology, or to any Affiliate
of such party, that shall be furnished to or obtained by the other party in


                                        1
<PAGE>


connection with this Agreement. Confidential Information shall not include any
information that: (i) at the time of disclosure, is generally available to the
public; (ii) after the time of disclosure, becomes generally available to the
public, except as a result of a breach of this Agreement by the recipient of
such information; (iii) prior to the time of disclosure, becomes available to
the recipient of such information from a third party which is not legally or
contractually prohibited from disclosing such Confidential Information;
provided, that such Confidential Information was not acquired, directly or
indirectly, from the disclosing party or its Affiliates; (iv) the recipient of
which can demonstrate was developed by or for such recipient independently of,
and without the use of, the Confidential Information disclosed by the disclosing
party or its Affiliates hereunder; or (v) is required to be disclosed by legal
or judicial process; provided, in each case, the party so disclosing information
timely informs the other party, uses its commercially reasonable efforts to
limit the disclosure required by such legal or judicial process, and permits the
other party to attempt, by appropriate legal means, to limit such disclosure.

                  "First Commercial Sale" means the first sale of the Product by
Leiner under this Agreement in an arms' length transaction to an unaffiliated
third party.

                  "Impax's Manufacturing Cost" means Impax and its Affiliates'
fully absorbed costs, relating to the Product consisting of raw and packaging
materials, labor and allocated overhead, based on the full absorption costing
allocation method. Each of these factors shall be determined in accordance with
Impax's customary cost accounting policies and practices and in a manner
consistent with U.S. generally accepted accounting principles.

                  "Ineligible Person" means any Person who is prohibited by any
law, rule or regulation or by any order, directive or policy from selling the
Product or any other pharmaceutical product within the Territory or who is
listed by any United States federal agency as debarred, suspended, proposed for
debarment or otherwise ineligible for federal programs in the United States or
other jurisdictions within the Territory.

                  "Leiner Facility" means the facility and warehouse to be used
by Leiner to process, package, label and/or store the Product.

                  "Leiner's Packaging Costs" means Leiner and its Affiliates'
fully absorbed costs, relating to the Product consisting of raw and packaging
materials, labor and allocated overhead, based on the full absorption costing
allocation method. Each of these factors shall be determined in accordance with
Leiner's customary cost accounting policies and practices and in a manner
consistent with U.S. generally accepted accounting principles and the
calculations set forth on Exhibit 6.2.

                  "Net Sales" means, for any given period, that dollar amount
determined by deducting the following reasonable and customary deduction items
from the gross invoiced sales price billed for the Product sold by Leiner and
its Affiliates in the Territory to unaffiliated third parties in arms length
transactions during the applicable period: (i) trade, quantity or cash
discounts, service allowances and independent brokers or agents' commissions, if
any, actually allowed or paid during the applicable period; (ii) credits or
allowances for the Product, if any, actually given or made on account of price
and shelf adjustments, returns, off-invoice promotional discounts (but excluding
all free goods provided to customers), rebates, chargebacks, any and all
federal, state or local government rebates or discounts whether in existence now
or enacted at any time hereafter, volume reimbursements, and the gross amount
billed for all rejected Product or Product recalled, seized or destroyed
(voluntarily or at the request of any government agency, subdivision or
department) during the applicable period; (iii) to the extent not included in
Impax's Manufacturing Costs or Leiner's Packaging Costs, any tax, excise or
other government charge upon or measured by the production, sale,
transportation, delivery or use of the Product during the applicable period; and
(iv) to the extent not included in Impax's Manufacturing Costs or Leiner's
Packaging Costs, any surcharge, levy, tax, or assessment mandated by any
federal, state or local government or administrative agency during the
applicable period to fund a compensation program or reserve for persons injured
by the Product, in each case determined in accordance with U.S. generally
accepted accounting principles. For purposes of clarification, the items
identified in clauses (i) and (ii) above, shall only be deducted from the gross
invoiced sales price if, and only to the extent, they are paid to customers with
respect to sales of the Product, and not for services or other unrelated
activities that would not be included in a gross to net sales calculation under
U.S. generally accepted accounting principles.




                                        2
<PAGE>

                  "Net Profit" means Net Sales of the Product in the Territory
during the applicable measurement period less: (i) Impax's Manufacturing Cost
applicable to such period; and (ii) Leiner's Packaging Cost applicable to such
period. Notwithstanding the foregoing, if in any period the amounts set forth in
(i) through (ii) above reduce Net Profit to zero or below, then these amounts
shall be deducted until Net Profit is zero and the balance of the costs shall be
deducted against Net Profits in future periods until such amounts have been
fully deducted; provided that such carryover costs for the Product may not be
deducted once the Agreement is terminated.

                  "Paragraph IV Litigation" means any litigation commenced in
respect of the Product in accordance with and within the time specified by
Section 505(j)(5)(B)(iii) of the Act following the manufacturer's submission to
the FDA of a certification in accordance with Section 505(j)(2)(A)(vii)(IV) of
the Act solely with regard to claims of infringement, invalidity and
unenforceability of any patent(s) in respect of the Product.

                  "Person" means an individual, corporation, partnership,
limited liability company or other entity.

                  "Plant" means the facility and warehouse used by Impax to
manufacture, package and/or store the Product.

                  "Specifications" means the terms and conditions applicable to
the Product and described in the ANDA for the Product, as the same may be
supplemented or amended from time to time.

                  "Territory" means all of the states comprising the United
States of America, plus the District of Columbia, the Commonwealth of Puerto
Rico, the U.S. Virgin Islands, Guam, Samoa and any other jurisdiction which is a
United States government protectorate wherein an ANDA approved by the FDA is
required to sell the Product in such jurisdiction. The term "Territory"
specifically includes any companies located within the above-stated areas that
maintain or otherwise supply entities outside of the Territory, and such
international sales are intended to be included within the Territory, provided
such Product meets with all legal and regulatory requirements of such country.

                  2.       LICENSE RIGHT AND FEES.

                  (a) Except as provided otherwise herein, Impax grants to
Leiner and its Affiliates in accordance with the terms and conditions of this
Agreement, the exclusive license (even as to Impax and its Affiliates) to
market, sell and distribute ("Market") the Product for all indications in the
Territory for the Term (as herein defined) and Leiner accepts the grant of such
exclusive Marketing license from Impax. Notwithstanding the exclusive Marketing
license set forth herein, Impax shall be permitted to manufacture and sell the
Product in the Territory to Wyeth, acting through its Wyeth Healthcare Consumer
Healthcare Division and Affiliates of Wyeth ("Wyeth"), pursuant to the terms of
a Development, License and Supply Agreement entered into between Impax and Wyeth
on June 1, 2002, as the same may be amended from time to time (the "Wyeth
Agreement"), and nothing in this Agreement shall be deemed to limit, in any way,
the ability of Impax to fulfill its obligations under the Wyeth Agreement. If in
any year during the Initial Term, Leiner shall fail to order for delivery during
such year at least [XXX]* tablets of the Product, the license granted herein
shall revert to a non-exclusive license. If Leiner shall fail to order for
delivery at least [XXX]* tablets of the Product during any Renewal Term, Leiner
shall have no further rights to renew this Agreement.

                  (b) Neither Leiner nor its Affiliates shall, directly or
indirectly during the Term, Market any Competing Product in the Territory.








-----------------------
* Filed under an application for confidential treatment.

                                        3
<PAGE>

                  (c) In consideration of the Marketing exclusivity granted to
Leiner as provided herein, upon the latter of July 24, 2004 or thirty (30) days
after execution of this Agreement, Leiner shall pay to Impax the sum of $[XXX]*
in immediately available funds, which Impax shall refund Leiner in full if Impax
shall have failed to supply Leiner with at least [XXX]* tablets by [XXX]*.
Additionally, Leiner shall pay Impax an increased percentage of Net Profit
([XXX]* percent ([XXX]*%), as set forth in Section 6.4 herein), until such time
as Impax has been paid $[XXX]* in excess of the [XXX]* percent ([XXX]*%) share
of Net Profits provided for in Section 6.4. In the event this increased Net
Profit share fails to result in the payment of $[XXX]* within thirty (30) months
after the First Commercial Sale, Leiner shall pay the outstanding sum (i.e., the
portion of the $[XXX]* described above not already paid to Impax) within thirty
(30) days after the expiration of such thirty (30) month period. Leiner may
elect to pay any sum remaining due on this $[XXX]* marketing exclusivity
consideration at any time during this initial thirty (30) month period, at which
time the allocation of Net Profits pursuant to Section 6.4 shall convert to a
[XXX]* percent ([XXX]*%) share for [XXX]*.

       3.     MANUFACTURE AND DISTRIBUTION.

                  3.1     MANUFACTURE AND SUPPLY BY IMPAX.

         Subject to the provisions of Section 4.1 and the Wyeth Agreement, Impax
shall use its Commercially Reasonable Efforts to timely manufacture and supply
to Leiner one hundred percent (100%) of Leiner's purchase order requests for the
Product, upon the terms and conditions set forth herein and pursuant to the
forecasts referred to in Section 4.1. The Product shall initially be supplied in
one thousand (1,000) count bottles until such time as the FDA grants Impax the
approval to ship Product in bulk form and blister packs. After receipt of such
approval, Impax shall ship Product in bulk form or blister packs, as requested
by Leiner.

                  3.2     PURCHASE AND MARKETING BY LEINER.

                  (a) Leiner shall use its Commercially Reasonable Efforts to
Market and sell the Product over-the-counter, in the Territory, such efforts to
be no less than the efforts used by Leiner in relation to its other products.

                  (b) Leiner will obtain all of its requirements of the Product
in the Territory from Impax, for a period of twelve (12) months, commencing upon
the date of First Commercial Sale.

                  (c) Leiner will obtain not less than eighty percent (80%) of
its annual requirements of the Product in the Territory from Impax, pursuant to
this Agreement, for the remainder of the term of this Agreement, after
expiration of the first twelve-(12) month period provided in sub-paragraph (b)
above, except as otherwise set forth herein (d) If at any time after the First
Commercial Sale, Impax has credible evidence that Leiner is not using
Commercially Reasonable Efforts to Market the Product in accordance with this
Agreement, Impax shall notify Leiner and if Leiner does not begin to use
Commercially Reasonable Efforts to continue to Market the Product within twenty
(20) days after such notice, then Impax, at its option, and as its sole and
exclusive remedy, may, upon written notice to Leiner, convert the manufacture
and supply of the Product, as provided in Section 3.1, to a non-exclusive
arrangement, and, in any case, Impax may allocate its supply of Product among
its customers in any manner it deems desirable.

                  3.3     CONTINUITY OF SUPPLY.

                  (a) Notwithstanding Section 3.2 above, Impax acknowledges
Leiner's need for continuity of supply and homogenous appearance and content of
the Product. Therefore, in the event that (i) Impax notifies Leiner of its
inability to ship Product or (ii) subject to the provisions of Section 4.1, over
a rolling two (2) month period, Impax is unable to supply ninety percent (90%)
of Product ordered by Leiner hereunder prior to sixty (60) days after Leiner's
requested delivery date, Leiner may purchase replacement product from a third
party source to make up for any deficiency in supply of the Product by Impax.







-----------------
* Filed under an application for confidential treatment.


                                        4
<PAGE>

Leiner will use Commercially Reasonable Efforts to limit contractual obligations
to purchase such replacement product, but in the event it is unable to do so,
Leiner may continue to purchase replacement product for the term of such
contract and that volume shall be deducted from Leiner's aforestated purchase
obligations with Impax. The foregoing provisions shall be Leiner's exclusive
remedy for the failure of Impax to timely supply Product to Leiner. If Leiner
exercises its rights under this Section 3.3, and so long as Leiner is purchasing
replacement product from a third party pursuant to this Section, Impax shall be
relieved of its exclusivity obligations hereunder. If Leiner submits valid
purchase orders under this Agreement for at least [XXX]* ([XXX]*) tablets of the
Product during any year of the Initial Term and Impax shall fail to deliver to
Leiner at least [XXX]* ([XXX]*) tablets of the Product in any such year, then
Leiner, upon notification to Impax, may terminate this Agreement in which event
this Agreement shall be deemed terminated and of no further force and effect and
neither Party shall have any further liability to the other hereunder, other
than those liabilities specifically referred to in this Agreement.

         4.       PURCHASING; DELIVERY.

                  4.1 FORECASTS. Attached as Exhibit 4.1 is Leiner's preliminary
non-binding forecast for each year of the Initial Term (defined in Section 11).
Leiner shall also provide to Impax a non-binding twelve (12)-month rolling
forecast, updated on a quarterly basis, of Leiner's estimated requirements of
the Product, the first such forecast to be provided at least three (3) months
before the First Commercial Sale, which shall be no later than [XXX]*. Subject
to Sections 3.2 and 4.2, Leiner shall be bound to only purchase the Product
pursuant to purchase orders submitted by it to Impax, provided that the quantity
of Product specified in the first three (3) months of such forecast shall
constitute a binding purchase order. If Leiner fails to give Impax rolling
forecasts as specified above, the prior three (3) months rolling forecast shall
apply and be binding. All purchase orders for a Product shall specify the
delivery date therefor, which delivery date shall be no sooner than ninety (90)
days following the receipt of such order by Impax.

                  4.2 PURCHASE ORDERS Leiner shall place orders for the Product
with Impax using Leiner's standard form of purchase order. This Agreement shall
constitute a non-cancelable purchase of [XXX]* tablets to be delivered at any
time, but by no later than [XXX]*. Each purchase order submitted to Impax by
Leiner shall specify the requested delivery date, which shall not be less than
ninety (90) days after the date such order is received by Impax. Each purchase
order placed shall constitute a firm obligation to purchase the ordered
quantities of the Product. Impax shall give Leiner written notice of its
inability, if applicable, to ship quantities so ordered within fifteen (15) days
after receipt of such purchase order. In the event such notice is not received
by Leiner, such purchase order shall be deemed accepted. If Impax notifies
Leiner that it is unable to fill such purchase order, it shall indicate the
portion of such purchase order Impax cannot supply by the requested delivery
date and specify alternative delivery dates. The terms and conditions of this
Agreement shall be controlling over any conflicting terms and conditions stated
in Leiner's purchase order or Impax's invoice or confirmation. Any other
document which shall conflict with or be in addition to the terms and conditions
of this Agreement is hereby expressly rejected (unless the parties shall have
mutually agreed to the contrary in writing in respect of a particular instance).

                  4.3      DELIVERY, EXPIRY DATING.

                  (a) Impax shall deliver Product in the package form described
in Section 3.1(a), as requested by Leiner in the applicable purchase order and
as addressed in the container closure as approved by the FDA.

                  (b) All Products shall be delivered in bulk containers, F.O.B.
the Leiner Facility, and risk of loss and title to the Product shall pass to
Leiner upon delivery of the Product to the Leiner Facility. Impax shall arrange
for shipping and/or transportation of the Product to the Leiner Facility and pay
all shipping and related costs, including insurance, and any customs duties and
other taxes related to delivery of the Product to Leiner. Until so delivered to
the Leiner Facility, Impax shall ensure that the Product is transported,
handled, stored and delivered in accordance with the Specifications, applicable
cGMP, all applicable FDA requirements and all federal, state and local laws of
the U.S., Guam, Puerto Rico and the U.S. Virgin Islands.










------------------
* Filed under an application for confidential treatment.


                                        5
<PAGE>

                  (c) Impax shall include in each shipment of the Product
hereunder a certificate of analysis that shall certify that the Product
contained in such shipment complies with the Specifications. Upon delivery of
the Product, the Product shall have a minimum of twenty (20) months prior to
expiry.

         5.       PACKAGING.

                  5.1 PACKAGING BY IMPAX. Impax shall package the Product as
described in Section 3.1(a), as requested by Leiner in its purchase order
requests for the Product, upon the terms and conditions set forth herein and
pursuant to the forecasts referred to in Section 4.1. Impax shall provide Leiner
with label copy and insert and/or outsert copy and artwork as approved by the
FDA.

                  5.2 PACKAGING BY LEINER. Leiner shall further package the
Product into appropriate configurations and stock keeping units ("SKUs") for
sale to its customers. Leiner shall ensure that the Product is packaged with
labels, product inserts or outserts and other labeling conforming to applicable
cGMP, the Product ANDA including, without limitation, approved labeling and
other FDA requirements and all other applicable rules and regulations.
Concurrently with the execution of this Agreement, the Parties will execute the
Labeling Agreement attached hereto as Exhibit 5.2. Leiner shall not be
financially or otherwise responsible for the labels and artwork that are
contained on the labels of the bulk Product supplied by Impax to Leiner pursuant
hereto.

         6.       PAYMENT TERMS.

                  6.1 IMPAX'S MANUFACTURING COST. The price to be paid by Leiner
 for Product hereunder (the "Price") shall be equal to Impax Manufacturing Cost
 and shall initially be as set forth in Exhibit 6.1 attached hereto and
 incorporated herein. Each April and October of each year during the Term, the
 parties shall review Impax's Manufacturing Costs and if there shall have been a
 change during the preceding six (6) month period, the parties shall revise
 Impax's Manufacturing Cost used in determining Net Profit accordingly. Any such
 change shall be implemented in June following the review in April and in
 January following the review in October.

                  6.2 LEINER'S PACKAGING COST. Leiner's Packaging Cost for the
Product shall initially be as set forth in Exhibit 6.2 as attached hereto and
incorporated herein. Simultaneously with the review regarding Impax's
Manufacturing Costs as set forth above, the parties shall review Leiner's
Packaging Costs and if there shall have been a change during the preceding six
(6) month period, the parties shall revise Leiner's Packaging Costs used in
determining Net Profit accordingly. Any such change shall be implemented in June
following the review in April and in January following the review in October.

                  6.3 INVOICING AND PAYMENT. Impax shall invoice Leiner for the
Price of the Product promptly after delivery of such Product. The Price shall be
due and payable by Leiner to Impax within thirty (30) days after delivery of the
Product to the Leiner Facility. In addition to its other rights and remedies,
Impax shall have the right to assess interest on amounts past due by more than
twenty (20) days at the rate of one and one half percent (1 1/2%) per month, or
the highest rate permissible by law, if lower.

                  6.4 ALLOCATION OF NET PROFITS. Leiner shall pay Impax, within
thirty (30) days of the end of each calendar quarter, an amount equivalent to
[XXX]* percent ([XXX]*%) of the Net Profits attributable to the sales of the
Product during the previous quarter until such time as the $[XXX]* marketing
exclusivity consideration as set forth in Section 2(c) above has been paid in
full. After that time and thereafter for the term of this Agreement, Leiner
shall pay Impax, within 30 days after the end of each calendar quarter, an
amount equal to [XXX]*% of the Net Profits attributable to the Sales of the
Product during such quarter. Such payment shall be accompanied by a written
statement setting forth in reasonable detail the basis for and calculation of
Net Profits for each month of the applicable calendar quarter including, without
limitation, Net Sales and Leiner's Packaging Costs. In addition, Leiner shall
provide such statement by the tenth (10th) calendar day of the following month.








-------------------
* Filed under an application for confidential treatment.

                                       6
<PAGE>


         7.       QUALITY ASSURANCE.

                  7.1     FACILITY MAINTENANCE; INSPECTION; REPORTS.

                  (a) Impax shall permit Leiner to conduct reasonable periodic
 visits to the Plant upon reasonable notice during normal business hours (no
 more than once annually during the Term), subject to confidentiality
 obligations set forth in Section 13, to discuss manufacturing and supply issues
 and for general inspection purposes.

                  (b) Leiner shall provide Impax access to the portions of the
 Leiner Facility where Product is packaged or stored upon reasonable notice,
 during normal business hours (no more than once annually during the Term) and
 subject to confidentiality obligations set forth in Section 13.

                  (c) Each party shall promptly provide the other with an
 unredacted copy (except identifying information regarding entities for whom
 such party is obligated to protect as confidential) of any FDA Form 483
 Establishment Inspection Report, NDA Field Alert Report, Warning Letter, or
 Notice of Violation Letter relating to the Product and any responses or other
 correspondence relating thereto.

                  (d) Each party shall notify the other Party of any Out of
 Specification ("OOS") testing results within three (3) business days.

                  7.2     FILING REQUIREMENTS AND MAINTENANCE.

                  (a) Impax shall promptly comply with all FDA filing and
reporting requirements with respect to the Product, including, without
limitation, all filing and reporting necessary to maintain the ANDA. Impax shall
be responsible for all stability studies as may be necessary or advisable
regarding storage of the Product in bulk containers or blisters.

                  (b) Leiner shall be responsible for compliance with all FDA
and other regulatory requirements concerning its labeling, packaging and
marketing activities including, without limitation, all stability studies
relating to Product packaged by it, except as stated on the bulk packaging of
the Product or as otherwise approved in writing by Impax.

         8.       WARRANTIES, INDEMNIFICATION AND INSURANCE.

                  8.1     REPRESENTATIONS, WARRANTIES AND COVENANTS.

                  (a) Impax makes the following representations, warranties and
covenants:

                          (i)       Impax has obtained final FDA approval to
                                    market the Product and is otherwise entitled
                                    and enabled to manufacture, distribute, and
                                    market the Product;

                          (ii)      The Product (1) shall be manufactured,
                                    labeled, packaged, stored and transported
                                    (prior to Leiner's receipt of Product) in
                                    conformance with all applicable requirements
                                    of the FDA (including cGMP) and with all
                                    applicable laws, (2) shall be manufactured,
                                    labeled and packaged in conformance with the
                                    Specifications, (3) shall not be adulterated
                                    or misbranded within the meaning of the Act,
                                    and (4) shall not be a product which would
                                    violate any section of the Act if introduced
                                    into interstate commerce;




                                        7
<PAGE>

                          (iii)     Impax shall provide Leiner with all
                                    appropriate documentation regarding shipping
                                    and storage of Products; and

                          (iv)      Impax shall retain all lot numbers and
                                    records as required by the FDA.

                  (b) LEINER makes the following representations, warranties and
covenants:

                          (i)       The Product (1) shall be further packaged
                                    and labeled, stored and marketed by Leiner
                                    in conformance with all applicable
                                    requirements of the FDA (including cGMP) and
                                    with all applicable laws, rules and
                                    regulations, (2) shall be stored, further
                                    packaged and labeled in conformance with the
                                    Specifications, (3) shall not, by Leiner's
                                    or its Affiliates' actions, be adulterated
                                    or misbranded within the meaning of the Act,
                                    and (4) shall not, by Leiner's or its
                                    Affiliates' actions, be a product which
                                    would violate any section of the Act if
                                    introduced into interstate commerce; and

                          (ii)      Leiner shall retain all lot numbers and
                                    records as required by the FDA.

                          (iii)     Leiner shall handle and warehouse all
                                    Product in compliance with the Drug
                                    Enforcement Administration ("DEA")
                                    regulations, but in no event shall the
                                    Product be handled or warehoused in any
                                    manner less secure than the manner in which
                                    Leiner secures its other controlled
                                    substances.

                  (c) Each party represents, warrants and covenants to the other
that:

                          (i)       such party is not debarred under the Generic
                                    Drug Enforcement Act of 1992 and that it
                                    does not and will not use in any capacity
                                    the services of any Person debarred under
                                    the Generic Drug Enforcement Act of 1992;
                                    neither such party, nor, to the best of its
                                    knowledge, any of its employees, agents or
                                    contractors, has engaged in any activity
                                    which could lead to it becoming debarred
                                    under the Generic Drug Enforcement Act of
                                    1992; and

                          (ii)      such party is duly authorized to execute and
                                    deliver this Agreement and consummate the
                                    transactions contemplated hereby, and this
                                    Agreement constitutes the valid and binding
                                    obligation of such party.

                  (d) Each party agrees to notify the other within 24 hours of
its receipt of a Form 483 report, or warning letter (or similar form or notice
from a government oversight authority) with respect to the matters contemplated
by this Agreement.
                  (e) Each party agrees to notify the other within 24 hours of
its receipt of a notice of an FDA inspection regarding the Product, or if no
advance notice is given, immediately at the beginning of such inspection.

                  (f) EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN THIS
AGREEMENT, IMPAX MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, CONCERNING THE PRODUCT, OR THE MERCHANTABILITY OR FITNESS THEREOF FOR
ANY PURPOSES.





                                        8
<PAGE>

                  8.2     INDEMNIFICATION.

                  (a) Impax agrees to indemnify, defend and hold harmless, and
to pay and reimburse Leiner, its Affiliates, and its and their respective
employees, agents and representatives (the "Leiner Indemnitees"), from and
against any and all liability, damage, loss, cost or expense, including
reasonable attorneys' fees (collectively "Losses"), resulting from any third
party claims, actions, lawsuits or other proceedings (collectively "Claims"),
brought against a Leiner Indemnitee to the extent relating, directly or
indirectly, to or occurring as a result of, (i) the willful misconduct or
negligence under or in connection with the performance of, or the breach of any
provision of, this Agreement by Impax or any Impax Indemnitee, or (ii) in any
manner related to the Product, including, without limitation, the manufacture,
use, handling, storage, sale or other disposition of the Product, except for
those Losses for which Leiner has an obligation to indemnify Impax pursuant to
subparagraph (b) below, as to which Losses each party shall indemnify the other
to the extent of their respective liability for such Losses.

                  (b) Leiner agrees to indemnify, defend and hold harmless,
Impax, its Affiliates, and its and their respective employees, agents and
representatives (the "Impax Indemnitees"), from and against any and all Losses,
resulting from any Claims brought against an Impax Indemnitee to the extent
relating directly or indirectly, to or occurring as a result of, (i) the willful
misconduct or negligence under or in connection with the performance of, or the
breach of any provision of, this Agreement by Leiner or any Leiner Indemnitee,
or (ii) in any manner related to Leiner's obligations under this Agreement with
respect to the Product, except for those Losses for which Impax has an
obligation to indemnify Leiner pursuant to subparagraph (a) above, as to which
Losses each party shall indemnify the other to the extent of their respective
liability for such Losses.

                  (c) If a Leiner Indemnitee or an Impax Indemnitee (each case
an "Indemnified Party") receives any written claim which it believes is the
subject of indemnity hereunder, the Indemnified Party shall, as soon as
reasonably practicable after forming such belief, give notice thereof to the
other party (the "Indemnifying Party"), including all particulars of such claim
to the extent known to the Indemnified Party; provided that the failure to give
timely notice to the Indemnifying Party as contemplated hereby shall not release
the Indemnifying Party from any liability to the Indemnified Party except to the
extent the Indemnifying Party is materially prejudiced in defending any claim by
such failure. The Indemnifying Party shall assume the defense of such claim with
counsel of its choice reasonably satisfactory to the Indemnified Party, and at
the cost of the Indemnifying Party. The Indemnified Party may participate in the
action through counsel of its choice, but the cost of such counsel shall be at
the expense of the Indemnified Party (unless the Indemnified Party is required
to retain counsel due to a non-waivable legal conflict). If the Indemnifying
Party does not so assume the defense of such claim, or, having assumed such
defense fails to vigorously prosecute such defense, the Indemnified Party may
assume such defense, with counsel of its choice, to be paid or reimbursed by the
Indemnifying Party to the extent that it is obligated to provide indemnification
hereunder.

                  (d) The Indemnified Party shall render all reasonable
assistance to the Indemnifying Party, and all reasonable out-of-pocket costs of
such assistance shall be promptly paid or reimbursed by the Indemnifying Party
to the extent that it is obligated to provide indemnification hereunder.

                  (e) No such claim shall be settled and no admission may be
made other than by the party defending the same, and then only with the consent
of the other party, which shall not be unreasonably withheld; provided that the
Indemnified Party shall have no obligation to consent to any settlement of any
such claim which imposes on the Indemnified Party any liability or obligation
which will not be assumed and performed in full by the Indemnifying Party.

                  (f) Except as otherwise provided in Paragraph 8.1(a) or
8.1(b), in the event of a court or governmental body, including without
limitation the FDA or any state government, orders that the manufacture or sale
of the Product as a whole or of any ingredient in the Product cease or limits
the manufacture or sale of the Product or any ingredient in the Product, Leiner
and Impax will share equally in any expenses associated with the removal of the
Product from the market and/or the modification of the Product and/or the
marketing or distribution of the Product as a result of the court or
governmental order. To the extent removal of the Product from the market or
limitation on the sale of the Product includes a recall of the Product, however,
the expenses of that recall shall be allocated as set forth in Paragraph 9.3. If
the Product can no longer be sold because of such an order, this Agreement will
terminate. In the event the court or governmental order places a limit on the
manufacture or sale of the Product that did not exist prior to the order, Leiner
and Impax will renegotiate in good faith the terms of this Agreement relevant to
such limit so as to preserve the intended economic benefit to Leiner under this
Agreement and will use their best efforts to reach an agreement on those terms.





                                        9
<PAGE>

                  (g) EXCEPT IN THE EVENT OF AND TO THE EXTENT OF LOSSES AWARDED
TO A THIRD PARTY IN CONNECTION WITH THE INDEMNIFICATION PROVISIONS SET FORTH IN
THIS SECTION 8.2, THE INDEMNIFYING PARTY SHALL NOT BE LIABLE TO THE INDEMNIFIED
PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL DAMAGES OR LOST PROFITS,
WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE,
ARISING OUT OF THE MANUFACTURE, STORAGE, SHIPPING, TRANSPORTATION, DELIVERY,
LABELING, SALE, MARKETING, DISTRIBUTION OR USE OF THE PRODUCT.

                  8.3 INSURANCE. Each of Leiner and Impax shall maintain, during
the Term (and any renewal thereof) and for three (3) years thereafter, general
liability insurance, including coverage for product liability and contractual
liability, in an amount not less than $10,000,000 per occurrence with a carrier
authorized to issue such insurance coverage in the United States, with the other
party named as an additional insured. Each party will furnish to the other, upon
request, a certificate of insurance evidencing compliance with the requirements
of this Section. Each party shall notify the other of any cancellation or
material change in such insurance not less than thirty (30) days prior to the
date of such cancellation or change. Nothing contained in this section shall
limit, or be deemed to limit, the liability or responsibility of Impax or Leiner
or any Person acting on behalf of Impax or Leiner for payment of damages
resulting from its acts, omissions, or other conduct or operations under this
Agreement.

                  8.4 PARAGRAPH IV LITIGATION. Solely with respect to matters
related to this Agreement, Impax will (a) undertake the defense of legal matters
relating to the Paragraph IV Litigation with regard to the Product and (b) be
fully responsible for the legal fees and expenses resulting directly from the
Paragraph IV Litigation and have ultimate decision making authority with regard
to the Paragraph IV Litigation, except to the extent such expenses, fees,
damages and other costs relate to, or arise out of, the willful misconduct or
negligence of Leiner, or a breach by Leiner of any representation, warranty or
covenant hereunder. Impax shall indemnify Leiner, its Affiliates, officers,
directors and employees for any and all expenses, fees, damages and other costs
incurred related to such Paragraph IV Litigation.

         9.       NON-COMPLIANT PRODUCTS.

                  9.1 ACCEPTANCE AND REJECTION. Leiner shall give written notice
to Impax of any non-compliance of the Product with the terms of this Agreement,
promptly upon the earlier of (i) its becoming aware of such non-compliance or
(ii) the date it should have become aware of such non-compliance. Failure to
provide such notice within thirty (30) days after knowledge of such
non-compliance shall constitute acceptance thereof. Any notice by Leiner that
any Product does not comply with the terms and conditions hereof shall be
accompanied by a true and correct copy of the results of any tests conducted by
Leiner thereon. Leiner and Impax shall cooperate in good faith to resolve any
disputes arising therefrom and in the event that the parties shall be unable to
resolve such dispute within thirty (30) calendar days from the date of Impax's
receipt of Leiner's notice of such non-compliance, the parties shall submit such
dispute to a mutually agreed-upon independent laboratory. The determination by
such laboratory shall be final and binding and the costs therefor shall be borne
by the non-prevailing party. Leiner shall not dispose of any Product claimed to
be non-compliant until final resolution of any dispute with respect thereto or
Impax's written consent. In the event Leiner requests Impax's consent to destroy
a reasonable percentage of disputed Product and Impax declines, Impax will pay
one hundred percent (100%) of the storage costs allocated to such Product if
Leiner is the prevailing party in the dispute. If Leiner is not the prevailing
party, Leiner shall pay one hundred percent (100%) of the storage costs. Impax
shall promptly replace any non-compliant Product, with compliant Product, at
Impax's sole cost and expense.

                  9.2 PRODUCT COMPLAINTS AND ADVERSE DRUG EXPERIENCES. Leiner
 shall be responsible for handling all Product complaints promptly and for
 notifying Impax of all such complaints promptly. Leiner shall notify Impax of
 any report of an adverse drug experience concerning the Product within two (2)
 business days of receipt of such report and provide Impax with such information
 as required by applicable law and/or as reasonably requested by Impax.




                                       10
<PAGE>

                  9.3     PRODUCT RECALL.

                  (a) Subject to Section 9.3(b), in the event of any recall or
seizure of the Product (the Recalled Product"), (as to which Impax shall have
the right to make all final decisions regarding any such recall or seizure, with
the approval of Leiner, which approval shall not be unreasonably withheld or
delayed), other than that arising out of, relating to, or occurring as a result
of, any act or omission by Leiner, Impax shall be solely responsible for such
Recalled Product and

                  (i)         for all Recalled Product shipped to Leiner but not
                              yet processed, Impax shall, at Impax's option,
                              replace the Recalled Product or refund the
                              applicable Impax Manufacturing Cost paid by
                              Leiner;

                  (ii)        for all Recalled Product that is Leiner's
                              work-in-process, Impax shall pay Leiner's
                              Packaging Cost plus reimburse Leiner for the
                              applicable Impax Manufacturing Cost paid by
                              Leiner; and

                  (iii)       for all Recalled Product that has been shipped to
                              Leiner's customer(s), Impax shall reimburse Leiner
                              for all returns, minus Leiner's share of
                              associated Net Profits,

plus reimburse Leiner for all verifiable transportation costs, if any, taxes
incurred, other than taxes on income, insurance, handling and reasonable and
verifiable out-of-pocket costs incurred by Leiner in respect of the return of
such Recalled Product.

                  (b) Subject to Section 9.3 (a), in the event of any recall or
seizure of any Product arising out of, relating to or occurring as a result of
any act or omission by Leiner, Leiner shall be solely responsible for Impax's
Manufacturing Costs, transportation expenses and taxes incurred (other than
taxes on income), insurance, handling and reasonable and verifiable
out-of-pocket costs incurred by Impax in respect of the return of such recalled
or seized Product.

                  (c) For purposes of this section, "recall" shall mean (i) any
action by Impax, Leiner or any of their respective Affiliates to recover title
to or possession of any Product sold or shipped and/or (ii) any decision by
Leiner not to sell or ship Product to third parties which would have been
subject to recall if it had been sold or shipped, in each case taken in the good
faith belief that such action was appropriate under the circumstances. For
purposes of this section, "seizure" shall mean any action by any governmental
agency or authority to detain or destroy Product.

                  (d) Impax and Leiner shall keep the other informed of any
notification or other information, whether received directly or indirectly,
which might affect the marketability, safety or effectiveness of the Product, or
which might result in liability or otherwise necessitate action on the part of
either party, or which might result in recall or seizure of the Product,
including, but not limited to, an OSS or any NDA Field Alert. Impax will be
responsible for assuring that such recall is completed with the FDA, unless the
recall is due to Leiner's action or omissions in which event Leiner will be so
responsible.

         10.      AUDIT.

                  10.1 LEINER'S RIGHT TO AUDIT. Impax shall maintain true and
complete books of account containing an accurate record of all data necessary
for proper assessment of Impax's Manufacturing Cost for the Product. Impax shall
provide Leiner with the right, through an independent certified public
accountant (except any to whom Impax has a reasonable objection), to examine
such books of account related to such cost at any time, (on one occasion with





                                       11
<PAGE>

respect to any calendar year) on reasonable prior written notice, within two (2)
years after the end of the calendar year in which the Products that are the
subject of such payment were delivered for sale in the Territory for the purpose
of verifying the accuracy of such cost. Impax may require such accountant to
execute a reasonable confidentiality agreement as a condition to providing
access to its books and records. In the event that such certified public
accountant shall have questions which are not in their judgment answered by such
books and records, the accountant shall have the right to confer with
representatives of Impax, including its Chief Financial Officer. The parties
agree that information furnished to Leiner as a result of any such examination
shall be limited to a written statement by such certified public accountant to
the effect that they have reviewed the books of account maintained by or on
behalf of Impax and either (a) Impax's calculations are correct or (b) setting
forth any required adjustments thereto. Subject to Section 15.1, Impax and
Leiner agree to be bound by the final result of such audit. If any such audit
shows any overpayment by Leiner, a correcting refund shall be made within
forty-five (45) days after receipt of the written statement described above and,
if such overpayment shall exceed five (5%) percent of any amount payable
hereunder or $10,000, whichever is greater, Impax shall bear all reasonable
costs of the audit.

                  10.2 IMPAX'S RIGHT TO AUDIT. Leiner shall maintain true and
 complete books of account containing an accurate record of all data necessary
 for proper assessment of the Net Profit payments. Impax shall have the right,
 through an independent certified public accountant (except any to whom Leiner
 has a reasonable objection), to examine Leiner's books of account related to
 such payment at any time, (on one occasion with respect to any calendar year)
 on reasonable prior written notice, within two (2) years after the end of the
 calendar year in which the Products that are the subject of such payment were
 delivered for sale in the Territory for the purpose of verifying the accuracy
 of such payment. Leiner may require such accountant to execute a reasonable
 confidentiality agreement as a condition to providing access to its books and
 records. In the event that such certified public accountant shall have
 questions which are not in their judgment answered by such books and records,
 the accountant shall have the right to confer with representatives of Leiner,
 including its Chief Financial Officer. The parties agree that information
 furnished to Impax as a result of any such examination shall be limited to a
 written statement by such certified public accountant to the effect that they
 have reviewed the books of account of Leiner and either (a) Leiner's
 calculations are correct or (b) setting forth any required adjustments thereto,
 subject to Section 15.1. Impax and Leiner agree to be bound by the final result
 of such audit. If any such audit shows any underpayment by Leiner, a correcting
 payment shall be made within forty-five (45) days after receipt of the written
 statement described above and, if such underpayment shall exceed five (5%)
 percent of any amount payable hereunder or $10,000, whichever is greater,
 Leiner shall bear all reasonable costs of the audit.

         11. TERM. This Agreement is effective on the date hereof and shall
continue for a period of thirty-six (36) months from the date of First
Commercial Sale (the "Initial Term"); provided, however, that this Agreement
shall terminate automatically if there shall be no First Commercial Sale by
[XXX]*. Thereafter, this Agreement shall be automatically renewed for four (4)
successive twelve (12)-month periods (each, a "Renewal Term"), unless a party
shall otherwise notify the other in writing at least three (3) months prior to
the expiration date of the Initial Term or any Renewal Term. The Initial Term
and Renewal Terms are collectively referred to herein as the "Term".

         12.      TERMINATION.

                  12.1 TERMINATION. In addition to the termination provision set
forth in Section 11, this Agreement may be terminated during the Initial Term or
any Renewal Term upon the occurrence of the following events:

                  (a) Infringement. Either party may terminate this Agreement
upon twenty (20) days written notice to the other if, based upon the opinion of
qualified counsel, such party believes that the Product or API infringes the
intellectual property rights of a third party.












-----------------------
* Filed under an application for confidential treatment.


                                       12
<PAGE>

                  (b) Breach. If either party commits a breach or default in any
material respect in the performance or observance of any of its obligations
under this Agreement and such breach or default is not cured within thirty (30)
days after receipt by such party of the written notice from the non-breaching
party specifying the breach or default, then the non-breaching or non-defaulting
party may terminate this Agreement with immediate effect by giving written
notice to the breaching or defaulting party.

                  (c) Bankruptcy. This Agreement shall automatically terminate
upon the initiation of any proceeding in bankruptcy, reorganization or
arrangement for the appointment of a receiver or trustee to take possession of
the assets of a party hereto or similar proceeding under the law for release of
creditors by or against a party hereto, or if a party hereto shall make an
assignment for the benefit of its creditors.

                  (d) Force Majeure Event. If, as a result of a Force Majeure
Event, a party does not perform its obligations hereunder for any consecutive
period of sixty (60) days, the other party shall have the right to terminate
this Agreement in its entirety upon providing written notice to the
non-performing party, such termination to be effective ten (10) days after such
notice.

                  (e) Ineligible Person. (i) In the event that Leiner or Impax
or an Affiliate of either of them shall become an Ineligible Person with respect
to the Product, such party shall promptly notify the other in writing and shall
keep the other apprised of its reasonable best efforts to have the status as an
Ineligible Person removed, and the other party may terminate this Agreement upon
thirty (30) days prior written notice unless the status as an Ineligible Person
is removed within such period. (ii) Leiner or Impax may terminate this
Agreement, without penalty, upon thirty (30) days' prior written notice to the
other party if (otherwise than by reason of a breach of its obligations
hereunder) it is legally prohibited from performing its obligations hereunder or
it or one of its Affiliates shall become an Ineligible Person in respect of the
Product (and it has made its reasonable best efforts to remove the prohibition
or its status as an Ineligible Person) and such prohibition or status as an
Ineligible Person has continued uninterrupted for a period of 120 days.

                  (f) Form 483. The non-receiving party may terminate this
Agreement upon ninety (90) days notice if the other party has received a Form
483 report regarding Product or the manufacturing facilities therefor and it has
not complied with such Form 483 within a reasonable time thereafter and is not
diligently pursuing corrective action in response thereto or is not actively
contesting the deficiencies noted in the Form 483.

                  12.2     POST-TERMINATION.

                  (a) Upon the expiration or termination of this Agreement for
any of the above reasons, and subject to the ongoing confidentiality obligations
under Section 13 of this Agreement, the parties shall be permitted to continue
in their respective businesses as if the Agreement has not been entered into at
all, except that Leiner shall be allowed to sell its then-existing inventory of
the Product (including product shipped but not yet received), contingent upon
payment of any Net Profits payments due to Impax upon such post-termination
sales.

                  (b) Expiration or termination of this Agreement shall not
relieve the parties of any obligations accruing prior to the effective date
thereof or resulting therefrom. All payment obligations due pursuant to this
Agreement shall survive termination of this Agreement.

       13.        CONFIDENTIALITY.

                  13.1 TREATMENT OF CONFIDENTIAL INFORMATION. Except as required
by applicable laws and regulations or as otherwise provided in this Section 13,
during the Term and any Renewal Term, and for a period of five (5) years after
the termination or expiration of this Agreement, each party shall hold in strict
confidence, and may not use for purposes other than this Agreement, exploit or
disclose to a third party (except as specifically set forth herein or with the
express prior written consent of the other party) any and all Confidential
Information of the other party.






                                       13
<PAGE>

                  13.2     LIMITS ON DISCLOSURE.

                  (a) Without limiting the generality of the foregoing, each
party may disclose Confidential Information, to those employees who need to
receive the Confidential Information in order to further the activities
contemplated in this Agreement. Each party shall take sufficient precautions to
safeguard the Confidential Information. Each party understands and agrees that
the disclosure of Confidential Information may result in serious and irreparable
damage to the other party, that the remedy at law or any breach of this covenant
may be inadequate, and that the party seeking redress hereunder shall be
entitled to injunctive relief, without prejudice to any other rights and
remedies to which such party may be entitled.

                  (b) It is acknowledged that Confidential Information may be
obtained by a party from the other party not only in writing or other tangible
form (including electronic), but also through discussions between each party's
respective representatives, demonstrations, observations and memorization and
other intangible methods.

                  (c) The above notwithstanding, each party shall have the right
with the exercise of discretion, and insofar as practical under written
confidentiality agreements having provisions no less stringent than those
contained herein, to make disclosures of such portions of Confidential
Information to third party consultants, attorneys, contractors, advisors,
Affiliates and governmental agencies where, in the recipient's reasonable
judgment, such disclosure is beneficial to development, approval or marketing of
the Product pursuant to this Agreement.

                  (d) Except as otherwise set forth in this Agreement, upon the
expiration or termination of this Agreement and at the written request of the
disclosing party, the receiving party shall return all Confidential Information
of the disclosing party (including all copies, excerpts and summaries thereof
contained on any media) or destroy such Confidential Information at the option
of the disclosing party, with one copy retained by legal counsel.

       14.    FORCE MAJEURE.

                  14.1 EFFECTS OF FORCE MAJEURE. No party hereto shall be held
liable or responsible for failure or delay in fulfilling or performing any of
its obligations under this Agreement (other than the payment of money) if such
failure or delay is caused by, without limitation, acts of God, acts of the
public enemy, fire, explosion, flood, drought, war, terrorists, riot, sabotage,
embargo, strikes or other labor disputes, or by any other event or circumstance
of like or different character to the foregoing beyond the reasonable control
and without the fault or negligence of the affected party, or by intervention of
governmental agency (a "Force Majeure Event"). Such excuse shall continue as
long as the Force Majeure Event continues. Upon cessation of such Force Majeure
Event, such party shall promptly resume performance hereunder.

                   14.2 NOTICE OF FORCE MAJEURE. Each party agrees to give the
 other party prompt written notice of the occurrence of any Force Majeure Event,
 the nature thereof and the extent to which the affected party will be unable to
 perform its obligations hereunder. Each party further agrees to use reasonable
 commercial efforts to correct (if it is amenable to correction) the Force
 Majeure Event as quickly as possible and to give the other parties, including
 Leiner, prompt written notice when it is again fully able to perform such
 obligations.

                  14.3 ALLOCATION OF CAPACITY. Notwithstanding anything to the
 contrary contained in this Agreement, Leiner acknowledges that the Wyeth
 Agreement requires Impax to accommodate any Wyeth request for Product and that
 throughout the term of the Wyeth Agreement, Wyeth shall be a preferred customer
 and has priority over all other parties, including Leiner and its Affiliates,
 with regard to the supply of the Product.






                                       14
<PAGE>

         15.      MISCELLANEOUS.

                  15.1 DISPUTE RESOLUTION. The parties recognize that a bona
fide dispute as to matters may, from time to time, arise during the term of this
Agreement which relates to a party's rights and/or obligations hereunder. In the
event of the occurrence of such a dispute, either party may, by notice to the
other party, have such dispute referred to their respective officers, designated
below, or their successors, for attempted resolution by good faith negotiation
within thirty (30) days after such notice is received. Such designated officers
are initially as follows:

         For Leiner:                Robert M. Fisher, Senior Vice President

         For Impax:                 David S. Doll, Senior Vice President

If no agreement is reached within 30 days of the referral to such officers, then
such controversy or claim shall be settled by arbitration in accordance with the
Commercial Arbitration Rules of the American Arbitration Association, such
arbitration to be held on an expedited basis either in San Francisco,
California, if such dispute is initiated by Leiner or in Los Angeles County,
California, if such arbitration is initiated by Impax. Judgment upon the award
rendered by the arbitrator(s) shall be final, binding and conclusive as between
the parties and may be entered in any court having jurisdiction thereof. The
arbitrators shall have the discretion, to be exercised in accordance with
applicable law, to allocate among the parties the arbitrators' fees and
litigation costs, and the arbitrators shall also have authority to shift the
prevailing party's attorney's fees to the non-prevailing party. The obligation
to arbitrate under this Section 15.1 shall not apply to any proceedings that
seek equitable or injunctive relief under this Agreement.

              15.2 GOVERNING LAW. This contract shall be governed by, and
 construed in accordance with, the laws of the State of Delaware, without giving
 effect to principles of conflicts of law. In connection with any action at law
 or in equity including any action which seeks injunctive relief, commenced
 hereunder, each of the undersigned consents to the jurisdiction of the state
 and federal courts located in Delaware and agree that service of process by
 certified mail, return receipt requested, shall constitute personal service for
 all purposes hereof. The parties hereby irrevocably waive all rights to a jury
 trial under any dispute under this Agreement.

              15.3 INDEPENDENT CONTRACTORS. The relationship between the parties
Impax on the one hand and Leiner on the other hand, is that of independent
contractors and nothing herein shall be deemed to constitute the relationship of
partners, joint venturers nor of principal and agent between Impax and Leiner.
Neither party shall have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of the other party or to bind
the other party to any contract, agreement or undertaking with any third party.

              15.4 ASSIGNMENT. This Agreement may be assigned by either party in
connection with any sale, merger or other business combination involving all or
substantially all of the parties' assets or stock. Except as set forth in the
preceding sentence, neither this Agreement nor any other rights nor obligations
hereunder shall be assigned, delegated or subcontracted by either party by
operation of law or otherwise without the prior written consent of the other
party.

              15.5 PAYMENT CURRENCY. All amounts invoiced and all payments made
hereunder shall be in U.S. dollars. Any cost or expense that forms the basis of
a payment hereunder which was incurred in a currency other than U.S. dollars
shall be converted into its U.S. dollar equivalent in accordance with the usual
procedures therefor used by the Person incurring such cost or expense.

              15.6 NO IMPLIED WAIVER. No failure or delay on the part of the
 parties hereto to exercise any right, power or privilege hereunder or under any
 instrument executed pursuant hereto shall operate as a waiver; nor shall any
 single or partial exercise of any right, power or privilege preclude any other
 or further exercise thereof or the exercise of any other right, power or
 privilege.




                                       15
<PAGE>


              15.7 NOTICE. All notices required to be given hereunder shall be
in writing and shall be given by personal delivery, via facsimile transmission,
by a nationally recognized overnight carrier or by registered or certified mail,
postage prepaid with return receipt requested. Notices shall be addressed to the
parties as follows:


                  If to Leiner:     Leiner Health Products, LLC
                                    901 East 233rd Street
                                    Carson, California 90745
                                    Attn: President
                                    Facsimile No.: (310) 952-7763

                                    With a copy to:

                                    Leiner Health Products, LLC
                                    901 East 233rd Street
                                    Carson, California 90745
                                    Attn: Legal Department
                                    Facsimile No.: (310) 835-9458


                  If to Impax:      Impax Laboratories, Inc.
                                    121 New Britain Boulevard
                                    Chalfont, PA 18914
                                    Attn: David Doll, Senior Vice President
                                    Facsimile No.: (215) 933-0333

                                    with a copy to:

                                    Blank Rome LLP
                                    18th & Cherry Streets
                                    One Logan Square
                                    Philadelphia, PA 19103
                                    Attn:  Ronald Fisher, Esq.
                                    Facsimile No.: (215) 832-5479

Notices delivered personally shall be deemed communicated as of actual receipt;
notices sent via facsimile transmission shall be deemed communicated as of
receipt by the sender of written confirmation of transmission thereof; notices
sent via overnight courier shall be deemed received as of one business day
following sending; and notices mailed shall be deemed communicated as of three
business days after proper mailing. A party may change his or its address by
written notice in accordance with this section, but such notice shall be deemed
communicated as of actual receipt.

              15.8 AMENDMENTS. Any amendment or modification of this Agreement
shall be valid only if made in writing and signed by all parties hereto.

              15.9 COUNTERPARTS. This Agreement may be executed in counterparts,
each of which shall be deemed an original and all of which shall constitute a
single document.

              15.10 ENTIRE AGREEMENT. This Agreement, including the Exhibits
 hereto which are incorporated herein as if set forth in their entirety at the
 point of reference thereto, constitutes the entire understanding between the
 parties with respect to the subject matter hereof and supersedes all prior
 contracts, agreements and understandings related to the same subject matter
 between the parties. The parties make no representations or warranties, except
 as expressly provided herein. The parties intend this Agreement to be a
 complete statement of the terms of their understanding. No change or
 modification of any of the provisions hereof shall be effective unless in
 writing and signed by an authorized officer of each of the parties.





                                       16
<PAGE>

              15.11 BENEFIT; BINDING EFFECT. This Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns.

              15.12 SURVIVAL. Notwithstanding anything to the contrary contained
in this Agreement, the provisions of Sections 1, 8, 9, 10, 12.2, 13, and 15
shall survive any termination of this Agreement.

              15.13 FURTHER ASSURANCES. The parties hereto agree that they shall
take all appropriate actions, including, without limitation, the execution or
filing of any documents or instruments, which may be reasonably necessary to
carry out the intent and accomplish the purposes of any of the provisions
hereof.

              15.14 SEVERABILITY. In the event that any provision of this
Agreement or part thereof shall be held invalid or unenforceable for any reason
by a court of competent jurisdiction, such provision or part thereof shall be
considered separate from the remaining provisions of this Agreement, which shall
remain in full force and effect. Such invalid or unenforceable provision shall
be deemed revised to effect, to the fullest extent permitted by law, the intent
of the parties as set forth therein.

               15.15 PRESS RELEASES; DISCLOSURES. Except those required by
applicable law, any and all press releases, publicity or other form of public
written disclosures relating to this Agreement shall be mutually agreed to by
the parties (the consent of a party not to be unreasonably withheld or unduly
delayed and in any event a party shall respond within two (2) business days of
receiving a request, failing which it shall be deemed to have consented)
including, if applicable, the time of release of such public written disclosures
as well as the content of such public written disclosures. For releases or
announcements required by applicable law, the party making the release or
announcement shall, before making any such release or announcement, afford the
other party a reasonable opportunity to review and comment. Any copy of this
Agreement to be filed with the Securities and Exchange Commission or any other
governmental entity shall be redacted to the fullest extent permitted by
applicable law; provided, however, in the event that the Securities and Exchange
Commission or other governmental entity, as applicable, objects to the redaction
of any portion of this Agreement after the initial submission, the filing party
shall inform the other party of the objections and shall in good faith respond
to the objections in an effort to limit the disclosure required by the
Securities and Exchange Commission or governmental entity, as applicable.



                      [signatures appear on following page]


















                                       17
<PAGE>





                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be executed as of the date first above written by their duly
authorized representatives.


                                    LEINER HEALTH PRODUCTS, LLC



                                    By: /s/ Gale K. Bensussen
                                       ------------------------------
                                       Name:  Gale K. Bensussen
                                       Title: President
                                       Date:

                                    LEINER HEALTH PRODUCTS, LLC



                                    By: /s/ Robert M. Fisher, Jr.
                                       ------------------------------
                                       Name:  Robert M. Fisher, Jr.
                                       Title: Senior Vice President
                                       Date:


                                    IMPAX LABORATORIES, INC.


                                    By: /s/ David Doll
                                       ------------------------------
                                       Name:  David Doll
                                       Title: Senior Vice President
                                       Date:












                                       18